Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to “Strong-Buy”

Royalty Pharma (NASDAQ:RPRX – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a report issued on Saturday, Wall Street Zen reports.

RPRX has been the topic of a number of other research reports. Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, September 14th. Citigroup increased their price target on Royalty Pharma from $70.00 to $78.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. The Goldman Sachs Group restated a “buy” rating and set a $66.00 price objective on shares of Royalty Pharma in a research report on Thursday, August 6th. Bank of America reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded Royalty Pharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $63.29.

Get Our Latest Stock Report on RPRX

Royalty Pharma Stock Performance

Royalty Pharma stock opened at $69.31 on Friday. The business has a 50 day moving average of $61.51 and a 200-day moving average of $54.53. The company has a market capitalization of $39.76 billion, a P/E ratio of 57.76, a P/E/G ratio of 1.37 and a beta of 0.36. Royalty Pharma has a 1 year low of $37.31 and a 1 year high of $70.37. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.29 and a quick ratio of 1.29.

Insiders Place Their Bets

In other Royalty Pharma news, EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the sale, the executive vice president directly owned 270,401 shares of the company’s stock, valued at approximately $15,826,570.53. The trade was a 27.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 4,126 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $57.10, for a total transaction of $235,594.60. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 208,252 shares of company stock valued at $12,324,407 over the last 90 days. Corporate insiders own 18.84% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Hsbc Holdings PLC raised its holdings in shares of Royalty Pharma by 2,562.2% in the first quarter. Hsbc Holdings PLC now owns 1,544,018 shares of the biopharmaceutical company’s stock valued at $74,000,000 after purchasing an additional 1,486,020 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Royalty Pharma during the first quarter worth about $37,941,000. Bank of America Corp DE boosted its holdings in Royalty Pharma by 29.0% during the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company’s stock worth $167,696,000 after purchasing an additional 786,921 shares during the last quarter. Carmignac Gestion purchased a new position in Royalty Pharma during the first quarter worth about $30,279,000. Finally, Congress Asset Management Co. bought a new stake in Royalty Pharma in the 3rd quarter worth about $30,761,000. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.

Further Reading

Analyst Recommendations for Royalty Pharma (NASDAQ:RPRX)

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.